Pfizer Inc.
Explore Pfizer
Core profile pages, annual revenue records, and related research hubs for this company.
Pfizer Inc.
Explore Pfizer
Core profile pages, annual revenue records, and related research hubs for this company.
Business Model Analysis
Annual Revenue: $62.58B
Pfizer operates a prominent, volume-driven biopharmaceutical model. It relies entirely on large scale. The company does not simply rely on slow internal R&D; it operates as a substantial M&A engine, aggressively acquiring smaller biotech firms that have promising drugs, and then using its unparalleled global manufacturing and sales force to maximize the commercial revenue before the patents expire.
Pfizer growth strategy emphasizes oncology, vaccines, internal medicine, obesity and metabolic research, business development discipline, cost reduction, and global commercial execution. Chris Boshoff became Chief Scientific Officer and President, Research & Development effective January 1, 2025.
They discover, develop, manufacture, and heavily market prescription medications and vaccines. Their profit relies entirely on government-granted patents, which give them a temporary monopoly (usually 20 years) to charge high prices to recoup the massive costs of development.
The existential threat to all pharma companies. When a drug's patent expires, generic manufacturers (like Teva) instantly flood the market with cheap copies. The original drug's revenue can collapse by 90% in a single year. Pfizer is constantly racing to invent new drugs to replace the revenue lost over the cliff.
No. While they spend billions on internal R&D, their primary business model relies heavily on acquisitions. They frequently buy smaller biotech startups that have already discovered a promising drug, using Pfizer's massive scale to push the drug through FDA trials and market it globally.
To focus entirely on high-margin prescription drugs. In 2019, Pfizer merged its consumer health division (Advil, ChapStick, Centrum) with GSK, and later spun it off into a new company (Haleon). Wall Street prefers pure-play, high-margin biopharma companies over slow-growing consumer products.
A highly controversial process. They maximize price based on 'value to the healthcare system' (how much money the drug saves hospitals by preventing surgeries) and what insurance companies are willing to pay, leading to massive public anger over the astronomical cost of life-saving medicines.